257 related articles for article (PubMed ID: 15755593)
21. Meningococcal surrogates of protection--serum bactericidal antibody activity.
Borrow R; Balmer P; Miller E
Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600
[TBL] [Abstract][Full Text] [Related]
22. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials.
Martin D; McCallum L; Glennie A; Ruijne N; Blatchford P; O'Hallahan J; Oster P
Vaccine; 2005 Mar; 23(17-18):2218-21. PubMed ID: 15755599
[TBL] [Abstract][Full Text] [Related]
23. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.
O'Hallahan J; McNicholas A; Galloway Y; O'Leary E; Roseveare C
N Z Med J; 2009 Mar; 122(1291):48-59. PubMed ID: 19322255
[TBL] [Abstract][Full Text] [Related]
24. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
[TBL] [Abstract][Full Text] [Related]
25. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.
Trotter C; Findlow J; Balmer P; Holland A; Barchha R; Hamer N; Andrews N; Miller E; Borrow R
Clin Vaccine Immunol; 2007 Jul; 14(7):863-8. PubMed ID: 17494636
[TBL] [Abstract][Full Text] [Related]
26. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
Dyet K; Devoy A; McDowell R; Martin D
Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.
Sandbu S; Feiring B; Oster P; Helland OS; Bakke HS; Naess LM; Aase A; Aaberge IS; Kristoffersen AC; Rydland KM; Tilman S; Nøkleby H; Rosenqvist E
Clin Vaccine Immunol; 2007 Sep; 14(9):1062-9. PubMed ID: 17634513
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
29. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak.
Caron F; du Châtelet IP; Leroy JP; Ruckly C; Blanchard M; Bohic N; Massy N; Morer I; Floret D; Delbos V; Hong E; Révillion M; Berthelot G; Lemée L; Deghmane AE; Bénichou J; Lévy-Bruhl D; Taha MK
Lancet Infect Dis; 2011 Jun; 11(6):455-63. PubMed ID: 21489881
[TBL] [Abstract][Full Text] [Related]
30. Serum opsonins to serogroup B meningococci after disease and vaccination.
Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
[TBL] [Abstract][Full Text] [Related]
31. The strategy to control New Zealand's epidemic of group B meningococcal disease.
O'Hallahan J; Lennon D; Oster P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
[TBL] [Abstract][Full Text] [Related]
32. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B.
Pillai S; Howell A; Alexander K; Bentley BE; Jiang HQ; Ambrose K; Zhu D; Zlotnick G
Vaccine; 2005 Mar; 23(17-18):2206-9. PubMed ID: 15755596
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
[TBL] [Abstract][Full Text] [Related]
34. Recent developments in vaccines to prevent meningococcal serogroup B infections.
Vermont CL; van den Dobbelsteen GP; de Groot R
Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
[TBL] [Abstract][Full Text] [Related]
35. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
[TBL] [Abstract][Full Text] [Related]
36. Prevention of group B meningococcal disease by vaccination: a difficult task.
Thomas M
N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
[TBL] [Abstract][Full Text] [Related]
37. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
39. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory.
de Kleijn ED; de Groot R; Lafeber AB; Labadie J; van Limpt CJ; Visser J; Berbers GA; van Alphen L; Rümke HC
J Infect Dis; 2001 Jul; 184(1):98-102. PubMed ID: 11398116
[TBL] [Abstract][Full Text] [Related]
40. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.
Sierra GV; Campa HC; Varcacel NM; Garcia IL; Izquierdo PL; Sotolongo PF; Casanueva GV; Rico CO; Rodriguez CR; Terry MH
NIPH Ann; 1991 Dec; 14(2):195-207; discussion 208-10. PubMed ID: 1812432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
